Low levels of these chemokines within in a tumor contributes to a “cold” tumor landscape unable to respond to immune therapies such as checkpoint inhibitors, while high CXCL9/10 contributes to “hot” tumors where effector cells are present but may not function properly. This evidence concerns the gene CXCL9 and neoplasm.